DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteochondritis dissecans — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteochondritis dissecans maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteochondritis dissecans is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
aggrecan (ACAN) — ACAN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9DFF · 2.59 Å · ligand beta-D-glucopyranuronic acid (BDP). Experimental structure, not a prediction.
What the evidence adds up to
In a 2008 study of 42 skeletally immature patients (47 knees) with stable juvenile osteochondritis dissecans of the knee, a standard six-month nonoperative protocol of temporary immobilisation followed by bracing and activity restriction produced progressive healing in 34 (66%) of the 47 lesions. Sixteen lesions (34%) failed to show progression toward healing. Lesions that healed had a significantly smaller mean surface area (208.7 ± 135.4 mm²) than those that did not (288.0 ± 102.6 mm²; p = 0.05). A logistic regression model incorporating patient age, normalised lesion size, and presenting symptoms (giving-way, swelling, locking, or clicking) predicted healing status, but age itself was not a significant contributor (p = 0.25). The authors concluded that larger lesions and those accompanied by swelling or mechanical symptoms at presentation are less likely to heal with this regimen.
A 2023 overview describes osteochondritis dissecans as an acquired pathological condition of subchondral bone with unknown incidence, multifactorial aetiology (genetic and acquired risk factors), and variable presentation including trauma, insidious onset, and exercise-induced pain. The knee, ankle, and elbow are primarily affected, and early identification is emphasised to prevent future osteoarthritis. A 2000 report gives a prevalence of 0.01 to 0.06%, with men aged 16 to 36 most commonly affected; in the western hemisphere the knee is involved in 75% of cases, and within the knee the medial femoral condyle accounts for 70–80%. The same report classifies the disorder into four stages, from subchondral oedema (stage 1) to a free osteochondral joint fragment (stage 4), and states that conservative treatment may yield full recovery only in stage 1, while invasive treatment is considered from stage 2 onward.
What remains missing is prospective data on which patients, beyond lesion size and presenting symptoms, are most likely to benefit from nonoperative care, and whether newer imaging or biological markers could improve prediction. No randomised trial has compared conservative management with early surgical intervention for stable juvenile lesions, and the long-term risk of osteoarthritis after either approach is not quantified in these abstracts. Funding for such a trial, and for studies that stratify patients by lesion stage and location, would be needed to move beyond the current descriptive evidence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Bone and Joint Surgery · 2008 · 217 citations · open access
The Healing Potential of Stable Juvenile Osteochondritis Dissecans Knee Lesions
AbstractBACKGROUND: The purpose of the present study was to determine if patient age, lesion size, lesion location, presenting knee symptoms, and sex predict the healing status after six months of a standard protocol of nonoperative treatment for stable juvenile osteochondritis dissecans of the knee. METHODS: Forty-two skeletally immature patients (forty-seven knees) who presented with a stable osteochondritis dissecans lesion were included in the present study. All patients were managed with temporary immobilization followed by knee bracing and activity restriction. The primary outcome measure of progressive lesion reossification was determined from serial radiographs every six weeks, for up to six months of nonoperative treatment. A multivariable logistic regression model was used to determine potential predictors of healing status from the listed independent variables. RESULTS: After six months of nonoperative treatment, sixteen (34%) of forty-seven stable lesions had failed to progress toward healing. The mean surface area (and standard deviation) of the lesions that showed progression toward healing (208.7 +/- 135.4 mm(2)) was significantly smaller than that of the lesions that failed to show progression toward healing (288.0 +/- 102.6 mm(2)) (p = 0.05). A logistic regression model that included patient age, normalized lesion size (relative to the femoral condyle), and presenting symptoms (giving-way, swelling, locking, or clicking) was predictive of healing status. Age was not a significant contributor to the predictive model (p = 0.25). CONCLUSIONS: In two-thirds of immature patients, six months of nonoperative treatment that includes activity modification and immobilization results in progressive healing of stable osteochondritis dissecans lesions. Lesions with an increased size and associated swelling and/or mechanical symptoms at presentation are less likely to heal.
British Journal of Hospital Medicine · 2023 · 5 citations
Osteochondritis dissecans
AbstractOsteochondritis dissecans is a condition characterised by acquired pathological subchondral bone lesions and its incidence is unknown. It has a multifactorial aetiology, with a combination of genetic and acquired risk factors. It commonly presents in adolescents and young adults. Patients have variable presentations, including trauma, insidious onset and pain exacerbated by exercise. The joints primarily affected are the knee, ankle and elbow joint. Early identification is key to treatment and to prevent future osteoarthritis of the joint. This article gives an overview of the presentation, assessment and management of the juvenile form of osteochondritis dissecans.
Economía y salud: boletín informativo · 2000 · 0 citations
La declaración de Valencia
AbstractOsteochondritis dissecans is a disorder with a prevalence of 0.01 to 0.06 %. Men between 16 and 36 years of age are most commonly affected by it. In the western hemisphere, the knee is affected by this progressive disorder in 75 % of the cases, specifically the medial femoral condyle (70 - 80 %). The etiology is uncertain, although genetic defects, micro-trauma, ossification disorders and ischemia have been implicated. Pathogenetically, Osteochondritis dissecans is classified in four stages, whereas in stage one, there is merely a subchondrial edema. Without therapy this could lead to stage 4, with a free osteochondral joint fragment. Treatment is analogous with the stage of the disorder. Whereas conservative treatment may yield full recovery during stage 1, starting in stage 2, invasive treatment should be considered. When the cartilage surface remains intact retrograde procedures are indicated. If the cartilage is injured anterograde therapies, like the chondral or osteochondral transplantation, should be used.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
